Your session is about to expire
← Back to Search
Ropidoxuridine for Gastrointestinal Cancer
Study Summary
This trial looks at the side effects and best dosage of a drug that may make radiation therapy more effective for patients with gastrointestinal cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your bilirubin levels are within the normal range for the hospital or clinic where you are being treated.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I can take care of myself but might not be able to do heavy physical work.Your white blood cell count is at least 3,000 per microliter.I am HIV positive with a CD4 count of 250 or higher and on anti-viral therapy.I have advanced cancer in the digestive system and am eligible for radiation therapy for symptom relief without other simultaneous treatments.My kidney function, measured by creatinine or its clearance, is within the normal range.I am a woman who can have children and my pregnancy test is negative.I haven't had chemotherapy in the last 4 weeks and no prior radiation at the tumor site for this study.You are expected to live for more than 12 weeks.I do not have brain metastases.You are currently taking any experimental drugs.You have enough white blood cells called neutrophils in your body.I haven't had chemotherapy or radiotherapy in the last 4 weeks, or I've recovered from its side effects.Your platelet count is at least 100,000 per microliter.Your liver enzyme levels are not more than 2.5 times the normal range.
- Group 1: Treatment (ropidoxuridine, IMRT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the Pharmacological Study been certified by the FDA?
"There is limited evidence of safety and efficacy for this pharmacological study, thus receiving a score of 1 on our scale."
What is the current enrolment size of this clinical experiment?
"This trial is no longer enrolling patients - the initial posting was in February 2016, and it has not been updated since September 2022. However, 2017 studies with stage IV small intestinal cancer AJCC V7 are currently recruiting participants as well as 3 trials seeking those interested to partake in Pharmacological Studies."
Is this research endeavor open to new participants?
"At this point, no further participants are being sought for the clinical trial. It was initially posted on February 1st 2016 and last updated September 20th 2022. However, if you're in search of other studies, 2017 medical trials are actively recruiting patients diagnosed with stage iv small intestinal cancer ajcc v7 while 3 pharmacological studies remain open to new admissions."
What other research has been conducted regarding the pharmacological impact of this substance?
"Presently, 3 clinical trials are underway assessing Pharmacological Study. None have progressed to Phase 3 yet. Of the 24 locations conducting research on this drug, most are located in Providence, Rhode island."
Share this study with friends
Copy Link
Messenger